Journal of Neurology, Neurosurgery, and Psychiatry, 1993, Vol 56, 1219-1220

PAPERS

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

SM Alam, T Kyriakides, M Lawden and PK Newman
Department of Neurology, Middlesbrough General Hospital, Cleveland, UK.

A randomised double-blind placebo-controlled trial of intravenous methylprednisolone versus oral methylprednisolone at equivalent high dose was carried out on 35 patients with an acute relapse of multiple sclerosis (MS). After baseline evaluation each was randomly allocated to oral treatment and intravenous placebo or intravenous treatment and oral placebo, receiving 500 mg of methylprednisolone for five consecutive days and with reassessment at days five and twenty-eight. There was no significant difference in response when disability or functional scores were compared in the two groups. Adverse effects were minor and equally distributed. In this study oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS.

© 1993 by Journal of Neurology, Neurosurgery, and Psychiatry

This article has been cited by other articles:

				S M Leary, B Porter, and A J Thompson Multiple sclerosis: diagnosis and the management of acute relapses Postgrad. Med. J., May 1, 2005; 81(955): 302 - 308. [Abstract] [Full Text] [PDF]

				J. A. Palace MULTIPLE SCLEROSIS: THE GUIDE TO TREATMENT AND MANAGEMENT Brain, March 1, 2002; 125(3): 683 - 684. [Full Text] [PDF]

				V. I. Leussink, S. Jung, U. Merschdorf, K. V. Toyka, and R. Gold High-Dose Methylprednisolone Therapy in Multiple Sclerosis Induces Apoptosis in Peripheral Blood Leukocytes Arch Neurol, January 1, 2001; 58(1): 91 - 97. [Abstract] [Full Text] [PDF]

				D. M Miller, B. Weinstock-Guttman, F. Bethoux, J.-C. Lee, G. Beck, V. Block, L. Durelli, L. LaMantia, D. Barnes, F. Sellebjerg, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Multiple Sclerosis, August 1, 2000; 6(4): 267 - 273. [Abstract] [PDF]

				L. M. Metz, D. Sabuda, R. J. Hilsden, R. Enns, and J. B. Meddings Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis Neurology, December 1, 1999; 53(9): 2093 - 2093. [Abstract] [Full Text]

				A. C. Tselis and R. P. Lisak Multiple Sclerosis: Therapeutic Update Arch Neurol, March 1, 1999; 56(3): 277 - 280. [Full Text] [PDF]

				H L Tremlett, D K Luscombe, and C M Wiles Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom J. Neurol. Neurosurg. Psychiatry, September 1, 1998; 65(3): 362 - 365. [Abstract] [Full Text]

				M. J. Olek, O. A. Khan, R. G. Hart, and R. W. Beck Corticosteroids, Optic Neuritis, and Multiple Sclerosis N. Engl. J. Med., April 28, 1994; 330(17): 1238 - 1239. [Full Text]